1447723-65-0

Basic information

• Product Name: 2-(3,5-bis(4-methoxyphenyl)-1H-1,2,4-triazol-1-yl)-1-(4-(pyridin-2-yl)piperazin-1-yl)ethanone
• CAS NO: 1447723-65-0
• Molecular Weight: 484.558
• Mol File: 1447723-65-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-(3,5-bis(4-methoxyphenyl)-1H-1,2,4-triazol-1-yl)-1-(4-(pyridin-2-yl)piperazin-1-yl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3,5-bis(4-methoxyphenyl)-1H-1,2,4-triazol-1-yl)-1-(4-(pyridin-2-yl)piperazin-1-yl)ethanone(1447723-65-0)
• EPA Substance Registry System: 2-(3,5-bis(4-methoxyphenyl)-1H-1,2,4-triazol-1-yl)-1-(4-(pyridin-2-yl)piperazin-1-yl)ethanone(1447723-65-0)

Safety Data

• Hazardous Substances Data: 1447723-65-0(Hazardous Substances Data)

Upstream product

• 874-90-8 4-methoxybenzonitrile 
• 2039-09-0 3,5-bis(4-methoxyphenyl)-1H-1,2,4-triazole 
• 491837-81-1 2-chloro-1-(4-(pyridin-2-yl)piperazin-1-yl)ethan-1-one 

Relevant articles and documents

A practical base mediated synthesis of 1,2,4-triazoles enabled by a deamination annulation strategy

A rapid and efficient base mediated synthesis of 1,3,5-trisubstituted 1,2,4-triazoles has been developed using the annulation of nitriles with hydrazines, which can be expanded to a wide range of triazoles in good to excellent yields. Ammonia gas is liberated during the reaction, and halo and hetero functional groups as well as free hydroxyl and amino groups are tolerated in this transformation. A variety of alkyl and aryl-substituted nitriles can be functionalized with aromatic and aliphatic hydrazines employing this procedure. This finding provides a practical and useful strategy for the synthesis of various 15N-labeled 1,2,4-triazole derivatives, and two types of mGlu5 receptor pharmaceuticals can be easily assembled in a one-pot manner. This journal is

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.